BlackRock
STOK icon

BlackRock’s Stoke Therapeutics STOK Stock Holding History

BlackRock’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192M Buy
5,877,357
+491,643
+9% +$15.8M ﹤0.01% 1823
2026
Q1 		$175M Buy
5,385,714
+173,160
+3% +$5.68M ﹤0.01% 1756
2025
Q4 		$165M Sell
5,212,554
-774,887
-13% -$23.3M ﹤0.01% 1803
2025
Q3 		$141M Buy
5,987,441
+62,874
+1% +$1.08M ﹤0.01% 1886
2025
Q2 		$67.2M Buy
5,924,567
+62,131
+1% +$590K ﹤0.01% 2283
2025
Q1 		$39M Sell
5,862,436
-25,075
-0.4% -$234K ﹤0.01% 2512
2024
Q4 		$64.9M Buy
5,887,511
+317,361
+6% +$3.9M ﹤0.01% 2306
2024
Q3 		$68.5M Buy
5,570,150
+160,981
+3% +$2.28M ﹤0.01% 2292
2024
Q2 		$73.1M Buy
5,409,169
+1,550,706
+40% +$20.9M ﹤0.01% 2214
2024
Q1 		$52.1M Buy
3,858,463
+1,798,231
+87% +$10.9M ﹤0.01% 2412
2023
Q4 		$10.8M Sell
2,060,232
-146,278
-7% -$625K ﹤0.01% 3356
2023
Q3 		$8.69M Sell
2,206,510
-87,160
-4% -$573K ﹤0.01% 3418
2023
Q2 		$24.4M Buy
2,293,670
+448,175
+24% +$4.77M ﹤0.01% 2911
2023
Q1 		$15.4M Buy
1,845,495
+14,848
+0.8% +$134K ﹤0.01% 3097
2022
Q4 		$16.9M Buy
1,830,647
+123,444
+7% +$1.28M ﹤0.01% 3123
2022
Q3 		$21.9M Buy
1,707,203
+4,914
+0.3% +$78.3K ﹤0.01% 2982
2022
Q2 		$22.5M Buy
1,702,289
+279,937
+20% +$4.25M ﹤0.01% 3024
2022
Q1 		$29.9M Sell
1,422,352
-59,913
-4% -$1.2M ﹤0.01% 2909
2021
Q4 		$35.6M Buy
1,482,265
+69,147
+5% +$1.65M ﹤0.01% 2906
2021
Q3 		$35.9M Sell
1,413,118
-102,321
-7% -$2.85M ﹤0.01% 2883
2021
Q2 		$51M Sell
1,515,439
-144,673
-9% -$5.11M ﹤0.01% 2693
2021
Q1 		$64.5M Buy
1,660,112
+52
+0% +$2.96K ﹤0.01% 2459
2020
Q4 		$103M Buy
1,660,060
+423,844
+34% +$19.4M ﹤0.01% 2060
2020
Q3 		$41.4M Buy
1,236,216
+22,086
+2% +$631K ﹤0.01% 2408
2020
Q2 		$28.9M Sell
1,214,130
-156,656
-11% -$3.72M ﹤0.01% 2606
2020
Q1 		$31.4M Buy
1,370,786
+451,363
+49% +$11.2M ﹤0.01% 2349
2019
Q4 		$26M Buy
919,423
+300,663
+49% +$7.56M ﹤0.01% 2734
2019
Q3 		$13.3M Buy
618,760
+573,109
+1,255% +$16M ﹤0.01% 3053
2019
Q2 		$1.33M Buy
+45,651
New +$1.23M ﹤0.01% 3921

Other funds holding STOK

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock's STOK Position: Q2 2026 in Review

BlackRock increased its Stoke Therapeutics (STOK) stake by 9.1% in Q2 2026, buying an estimated $15.8M and bringing the position to 5,877,357 shares worth $192M. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

BlackRock first reported a position in STOK in Q2 2019 and has held it in 29 quarters since. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • BlackRock held 5,877,357 shares of Stoke Therapeutics worth $192M as of Q2 2026.
  • BlackRock bought 491,643 Stoke Therapeutics shares in Q2 2026, an estimated $15.8M.
  • Stoke Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1823 holding.
  • BlackRock first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.